Somewhat Positive Press Coverage Somewhat Unlikely to Affect NeoGenomics (NEO) Share Price

Media coverage about NeoGenomics (NASDAQ:NEO) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.4819589513012 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of analysts recently weighed in on the stock. Janney Montgomery Scott reissued a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 18th. BTIG Research downgraded shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research report on Monday, September 11th. Finally, Gabelli began coverage on shares of NeoGenomics in a research report on Thursday, August 24th. They issued a “buy” rating and a $9.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $10.33.

Shares of NeoGenomics (NASDAQ NEO) opened at $9.13 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.99 and a current ratio of 2.14. The stock has a market cap of $734.14, a PE ratio of 182.60, a PEG ratio of 11.41 and a beta of 0.85. NeoGenomics has a 12 month low of $7.12 and a 12 month high of $11.63.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The business had revenue of $63.05 million during the quarter, compared to analysts’ expectations of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.04 EPS. research analysts forecast that NeoGenomics will post 0.04 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://weekherald.com/2017/12/04/neogenomics-neo-receiving-somewhat-positive-news-coverage-study-shows.html.

NeoGenomics Company Profile

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply